Institute to be Directed by PacBio CSO Dr.
Include Single Molecule Real Time Biology User Facility
California, Inc. (NASDAQ: PACB) announced a bi-coastal collaboration to
advance clinical research through the
and Multiscale Biology to be led by
is the hub of genomics research at Mount Sinai, collaborating with 13
other disease oriented and core technology based Institutes at Mount
Sinai. One of the world’s foremost experts in computational biology, Dr.
Schadt will direct the Institute, and also continue in his role as Chief
Scientific Officer of Pacific Biosciences.
As part of the collaboration, a Single Molecule Real Time (SMRT™)
Biology User Facility will be established within the Institute.
Developed by Pacific Biosciences,
real-time analysis of biomolecules with single molecule resolution,
providing a window into biological processes that has not previously
been open for study.
“The large-scale generation and integration of multiple sources of
biological data combined with clinical information will expand our
ability to characterize disease, and ultimately help develop and improve
the diagnosis and treatment of patients. This is the primary research
mission of
M.D., Dean of
to Pacific Biosciences’ revolutionary technology and under the direction
of Dr. Schadt, the
at the forefront of the revolution in genetics and genomic sciences,
which will fundamentally change the practice of medicine.”
Dr. Schadt is an expert on the generation and integration of very
large-scale sequence variation, molecular profiling and clinical data in
disease populations for constructing molecular networks that define
disease states and link molecular biology to physiology. His research
has provided novel insights into what is needed to master diverse,
large-scale data collected on normal and disease populations in order to
elucidate the complexity of disease and make more informed decisions in
the drug discovery arena. He has contributed to a number of discoveries
relating to the genetic basis of common human diseases such as diabetes
and obesity, which have been widely published in leading scientific
journals.
“The alliance between PacBio and Mount Sinai, and my dual role working
with both organizations, will allow us to bring together the components
required to catapult a new paradigm for clinical research and
translational medicine,” said Dr. Schadt. “Multiscale data integration,
including genomic, expression, metabolite, protein, and clinical
information, will ultimately define the future of patient care. With our
intent to collaborate in areas such as newborn screening for rare
genetic disorders, infectious diseases and cancer we hope to accelerate
this revolution, starting by integrating clinical data with previously
untapped biological information to build new computational models for
predicting human disease.”
Dr. Schadt is also a founding member of Sage Bionetworks, an open access
genomics initiative designed to build and support databases and an
accessible platform for creating innovative dynamic disease
models. Prior to joining Pacific Biosciences in 2009, he was Executive
Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of
Senior Research Scientist at Roche Bioscience. He received his B.A. in
applied mathematics and computer science from
State University, his M.A. in pure mathematics from
California, Los Angeles (UCLA), and his Ph.D. in bio-mathematics from
The SMRT Biology User Facility at Mount Sinai will be equipped with
research and development versions of the PacBio SMRT technology
platforms. These systems, called Astros, have been used by Pacific
Biosciences and its collaborators to examine a number of important
biological processes including DNA sequencing, direct RNA sequencing,
protein translation and ligand binding. The
available for use by the
Multiscale Biology and other collaborators located in the eastern half
of
in
“With a strong commitment, shared vision, and extensive access to
patient samples, we believe Mount Sinai is a perfect partner to help
realize the promise of
For more information about
For more information about Pacific Biosciences, please visit www.pacificbiosciences.com.
About
and
School of Medicine is one of few medical schools embedded in a hospital
in
and 15 institutes, and ranks among the top 20 medical schools both in
The school received the 2009 Spencer Foreman Award for Outstanding
Community Service from the
About Pacific Biosciences
Pacific Biosciences’ mission is to transform the way humankind acquires,
processes and interprets data from living systems through the design,
development and commercialization of innovative tools for biological
research. The company has developed a novel approach to studying the
synthesis and regulation of DNA, RNA and proteins. Combining recent
advances in nanofabrication, biochemistry, molecular biology, surface
chemistry and optics, Pacific Biosciences has created a powerful
technology platform called single molecule, real-time, or SMRT™,
technology.
with single molecule resolution, which has the potential to transform
the understanding of biological systems by providing a window into these
systems that has not previously been open for scientific study.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking
statements may contain words such as “believe,” “may,” “estimate,”
“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of
these terms, or other similar expressions, and include the assumptions
that underlie such statements. Such statements include, but are not
limited to, statements regarding the Company’s
statements are subject to known and unknown risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements, including but not limited to risks discussed
from time to time in documents
has filed with the
risks identified under the section captioned “Risk Factors” in its
recently filed Quarterly Report on Form 10-Q. All forward-looking
statements are based on estimates, projections and assumptions as of the
date hereof. Pacific Biosciences undertakes no obligation to update any
forward-looking statements.
Photos/Multimedia Gallery Available: https://www.businesswire.com/cgi-bin/mmg.cgi?eid=6724091&lang=en
For
Center
Ian.Michaels@mountsinai.org
or
For
Pacific Biosciences:
Media:
For
Pacific Biosciences
nicole@bioscribe.com
or
Investors:
Pacific
Biosciences
ir@pacificbiosciences.com
Source: Pacific Biosciences
News Provided by Acquire Media